Rulan Griesel
University Of Cape Town And Groote Schuur Hospital
Cape Town, WC, South Africa
Cape Town, WC, South Africa
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
Antiviral Effect, Safety, and Tolerability of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor: Proof-of-Concept Trial.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: March 03, 2026
VH3810109 Efficacy, Safety, Pharmacokinetics, and Incidence of Antidrug Antibodies in Adults With HIV-1 Naive to Antiretroviral Therapy: BANNER Study Results.
Journal: The Journal of infectious diseases
Published: March 14, 2025
Clinical Pharmacokinetics and Safety of a New HIV-1 Capsid Inhibitor, VH4004280, After Oral Administration in Adults Without HIV.
Journal: Infectious diseases and therapy
Published: December 20, 2024
Longer-term virologic outcomes on tenofovir-lamivudine-dolutegravir in second-line ART.
Journal: Southern African journal of HIV medicine
Published: October 28, 2024
Clinical Pharmacokinetics and Safety of Orally Administered VH4011499, a New HIV-1 Capsid Inhibitor, in Adults Without HIV.
Journal: Infectious diseases and therapy
Published: October 24, 2024
Pharmacokinetics of Single-Dose Versus Double-Dose Dolutegravir After Switching From a Failing Efavirenz-Based Regimen.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: September 13, 2023
Relationship Between Tenofovir Diphosphate Concentrations in Dried Blood Spots and Virological Outcomes After Initiating Tenofovir-Lamivudine-Dolutegravir as First-Line or Second-Line Antiretroviral Therapy.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: August 22, 2023
Dolutegravir dosing with rifampicin - Authors' reply.
Journal: The lancet. HIV
Published: August 08, 2023
Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial.
Journal: The lancet. HIV
Published: December 22, 2022
Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: November 03, 2022
Recycling Tenofovir in Second-line Antiretroviral Treatment With Dolutegravir: Outcomes and Viral Load Trajectories to 72 weeks.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: June 20, 2022
Pharmacokinetic and pharmacogenetic associations with dolutegravir neuropsychiatric adverse events in an African population.
Journal: The Journal of antimicrobial chemotherapy
Published: April 20, 2022
Last Updated: 09/26/2026